Antibiotics involved in the occurrence of antibiotic-resistant bacteria: A nationwide multilevel study suggests differences within antibiotic classes

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 2, 2013, Pages 461-470

  Gbaguidi Haore, Houssein ^a,b,c   Dumartin, Catherine ^c,d,e   L'Hériteau, François ^f   Péfau, Muriel ^d   Hocquet, Didier ^a,b,c   Rogues, Anne Marie ^c,d,e   Bertrand, Xavier ^a,b,c   Alfandari, S ^g   Ali Brandemeyer, O ^g   Angora, P ^g   Boussat, S ^g   Carbonne, A ^g   Coignard, B ^g   Giard, V ^g   Jarno, P ^g   Lacave L ^g   Machut, A ^g   Maugat, S ^g   Nguyen, F ^g   Pefau M ^g   Remy, E ^g   Saby, K ^g   Savey, A ^g   Schlemmer, B ^g   Touratier, S ^g   Vaux, S ^g   more..

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c INSERM   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f Regional Coordinating Center for Nosocomial Infection Control   (France)

^g Paris and North Coordinating Center for Nosocomial Infection Control ^*

Author keywords

Antibiotic resistance; Antibiotic use; Multilevel modelling

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ARTICLE; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; FRANCE; HEALTH FACILITIES; HUMANS;

EID: 84872396906     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks406     Document Type: Article

References (42)

1. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
2. Goossens H, Ferech M, Vander Stichele R et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365: 579-87.
3. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5: 1033-48.
4. Weber SG, Gold HS, Hooper DC et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415-22.
5. Hsu LY, Tan TY, Tam VH et al. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother 2010; 54: 1173-8.
6. Vernaz N, Huttner B, Muscionico D et al. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. J Antimicrob Chemother 2011; 66: 928-35.
7. Muller A, Mauny F, Talon D et al. Effect of individual- and group-level antibiotic exposure on MRSA isolation: a multilevel analysis. J Antimicrob Chemother 2006; 58: 878-81.
8. Ray GT, Baxter R, DeLorenze GN. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacinnonsusceptible Pseudomonas aeruginosa. Clin Infect Dis 2005; 41: 441-9.
9. Gilbert DN, Kohlhepp SJ, Slama KA et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob Agents Chemother 2001; 45: 883-92.
10. Linde HJ, Lehn N. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J Antimicrob Chemother 2004; 53: 252-7.
11. Hocquet D, Muller A, Blanc K et al. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 1173-5.
12. Bhavnani SM, Callen WA, Forrest A et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am J Health Syst Pharm 2003; 60: 1962-70.
13. MacDougall C, Harpe SE, Powell JP et al. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 2005; 11: 1197-204.
14. Dumartin C, L'Heriteau F, Pefau M et al. Antibiotic use in 530 French hospitals: results from a surveillance network at hospital and ward levels in 2007. J Antimicrob Chemother 2010; 65: 2028-36.
15. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2009. http://www.whocc.no/ atc_ddd_index/ (04 February 2012, date last accessed).
16. Members of the SFM Antibiogram Committee. Comité de l'Antibiogramme de la Societe Française de Microbiologie report 2003. Int J Antimicrob Agents 2003; 21: 364-91.
17. Goldstein H. Multilevel Statistical Models. London: Edward Arnold, 2003.
18. Hilbe J. Negative Binomial Regression. Cambridge: Cambridge University Press, 2011.
19. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2010. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). http://ecdc.europa.eu/en/publications/Publications/1111_SUR_AMR_data.pdf.pdf (20 December 2011, date last accessed).
20. Pitout JD, Laupland KB. Extended-spectrum b-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
21. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66: 1-14.
22. Jacoby GA, Munoz-Price LS. The new b-lactamases. N Engl J Med 2005; 352: 380-91.
23. Schwaber MJ, Navon-Venezia S, Schwartz D et al. High levels of antimicrobial coresistance among extended-spectrum-b-lactamaseproducing Enterobacteriaceae. Antimicrob Agents Chemother 2005; 49: 2137-9.
24. Falagas ME, Karageorgopoulos DE. Extended-spectrum b-lactamaseproducing organisms. J Hosp Infect 2009; 73: 345-54.
25. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum b-lactamaseproducing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45: 3548-54.
26. Baumgartner JD, Glauser MP. Pharmacokinetic and microbial susceptibility studies of ceftriaxone. Eur J Clin Microbiol 1983; 2: 501-4.
27. Guggenbichler JP, Allerberger FJ, Dierich M. Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy. Padiatr Padol 1986; 21: 335-42.
28. Valverde A, Coque TM, Sanchez-Moreno MP et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum b-lactamaseproducing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769-75.
29. Lautenbach E, Patel JB, Bilker WB et al. Extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-71.
30. Dinubile MJ, Friedland I, Chan CY et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 443-9.
31. Muller A, Lopez-Lozano JM, Bertrand X et al. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae. J Antimicrob Chemother 2004; 54: 173-7.
32. Masterton RG. The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents 2009; 33: 105-10.
33. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49: 999-1005.
34. Monnet DL. Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Infect Control Hosp Epidemiol 1998; 19: 552-9.
35. Fortaleza CM, Freire MP, Filho Dde C et al. Risk factors for recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol 2006; 27: 901-6.
36. Carmeli Y, Troillet N, Eliopoulos GM et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-82.
37. Lopez-Dupla M, Martinez JA, Vidal F et al. Previous ciprofloxacin exposure is associated with resistance to b-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. Am J Infect Control 2009; 37: 753-8.
38. Strateva T, Yordanov D. Pseudomonas aeruginosa-a phenomenon of bacterial resistance. J Med Microbiol 2009; 58: 1133-48.
39. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
40. Livermore DM. Interplay of impermeability and chromosomal b-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 2046-8.
41. Kaye KS, Kanafani ZA, Dodds AE et al. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinoloneresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 2192-6.
42. Dumartin C, Rogues AM, Amadeo B et al. Antibiotic usage in south-western French hospitals: trends and association with antibiotic stewardship measures. J Antimicrob Chemother 2011; 66: 1631-7.